NIAMS: CORT (Psoriasis Center of Research Translation)

NIAMS：CORT（银屑病研究翻译中心）

• 批准号: 8126343
• 负责人: Kevin D Cooper
• 金额: $ 78.47万
• 依托单位: CASE WESTERN RESERVE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-24 至 2013-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8126343
• 关键词: NIAMS; CORT; Psoriasis; Center; Research

A Center of Research Translation in Psoriasis based at University Hospitals Case Medical Center will integrate a strong psoriasis and skin disease research base with a large existing cohort of psoriasis patients. $5M from the new University Hospitals Murdough Family Center for Psoriasis will further increase the capabilities and geography of the clinical referral network, and in combination with $2M from Case School of Medicine for recruitment in psoriasis, these resources comprise a substantial institutional commitment to the CORT. The Skin Diseases Research Center's cutaneous biology infrastructure and experience will accelerate the Case Psoriasis CORT's advances for psoriasis patient benefit. The translational projects envisioned will test innovative therapeutic interventions in psoriasis that are based upon new mechanistic findings. They also provide new pathogenetic information using biologic samples from patients and animal models. It is intended that each Project will generate therapeutic modalities that change the treatment of psoriasis patients. Project 1 is a novel photodynamic therapy (PDT) Phase I mechanistic, safety, and preliminary efficacy study which also develops a real-time patient-optimized therapy device. Project 2 is a basic study that determines novel roles for S100 proteins in the pathogenesis of psoriasis, including proof-of-principle testing of S100 and macrophage interplay in psoriasis skin on xenogenic transplants. Project 3 takes advantage of a novel transgenic mouse model of psoriasiform dermatitis to examine the potential role of VEGF, S100 A8/9 and vascular changes exacerbating psoriasis. Project 4 explores whether the new clinical finding that psoriasis patients are at higher cardiovascular risk is related to S100 A8/9 overexpression and addresses if aggressive psoriasis treatment directed at S100 serum levels improves cardiovascular risk. The studies will be supported by two project-focused scientific Cores in A) Statistics and B) Systems Biology, and by an Administrative Core. An Advisory Board with representation by both male and female patients, as well as parents, some of whom are also renowned scientists, will oversee the CORT and the P&F review. The CORT will thus bring a multidisciplinary team of translational physician scientists, nurses, community clinicians, laity, and basic scientists from different departments and disciplines together to apply the intellectual and scientific resources of the institution to new therapies for psoriasis patients.

位于大学医院凯斯医学中心的银屑病研究转化中心将把强大的银屑病和皮肤病研究基地与现有的大量银屑病患者整合起来。新大学医院默多夫家庭银屑病中心提供的 500 万美元将进一步提高临床转诊网络的能力和地理范围，再加上凯斯医学院用于银屑病招募的 200 万美元，这些资源构成了对 CORT 的实质性机构承诺。皮肤病研究中心的皮肤生物学基础设施和经验将加速 Case Psoriasis CORT 的进步，造福于银屑病患者。设想的转化项目将测试基于新机制发现的银屑病创新治疗干预措施。他们还利用患者和动物模型的生物样本提供新的致病信息。每个项目都旨在产生改变银屑病患者治疗的治疗方式。项目 1 是一项新型光动力疗法 (PDT) I 期机制、安全性和初步疗效研究，还开发了一种实时患者优化的治疗设备。项目 2 是一项基础研究，旨在确定 S100 蛋白在银屑病发病机制中的新作用，包括异种移植银屑病皮肤中 S100 和巨噬细胞相互作用的原理验证测试。项目 3 利用新型牛皮癣样皮炎转基因小鼠模型来研究 VEGF、S100 A8/9 和血管变化加剧牛皮癣的潜在作用。项目 4 探讨银屑病患者心血管风险较高的新临床发现是否与 S100 A8/9 过度表达有关，并探讨针对 S100 血清水平的积极银屑病治疗是否会改善心血管风险。这些研究将得到 A) 统计学和 B) 系统生物学两个以项目为重点的科学核心以及一个行政核心的支持。由男性和女性患者以及父母（其中一些也是著名科学家）代表组成的咨询委员会将监督 CORT 和 P&F 审查。因此，CORT 将汇集来自不同部门和学科的转化医学科学家、护士、社区临床医生、外行和基础科学家组成的多学科团队，将该机构的知识和科学资源应用于银屑病患者的新疗法。